Jeffries v. BioTE Medical, LLC

CourtDistrict Court, S.D. West Virginia
DecidedMarch 25, 2022
Docket2:21-cv-00635
StatusUnknown

This text of Jeffries v. BioTE Medical, LLC (Jeffries v. BioTE Medical, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jeffries v. BioTE Medical, LLC, (S.D.W. Va. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA CHARLESTON DIVISION

STACEY A. JEFFRIES and RANDALL A. JEFFRIES,

Plaintiffs,

v. CIVIL ACTION NO. 2:21-cv-00635

BIOTE MEDICAL, LLC,

Defendant.

MEMORANDUM OPINION AND ORDER

The Court has reviewed the Plaintiffs’ Motion to Remand (Document 23), the Plaintiffs’ Memorandum of Law in Support of Motion to Remand (Document 24), BioTE Medical LLC’s Memorandum in Opposition to Plaintiffs’ Motion to Remand (Document 36), and the Plaintiffs’ Reply to Defendant’s Memorandum in Opposition to Plaintiffs’ Motion to Remand (Document 40). For the reasons stated herein, the Court finds that the motion to remand should be granted. FACTS AND PROCEDURAL HISTORY The Plaintiffs filed this action on September 2, 2021, in the Circuit Court of Kanawha County, West Virginia. The initial Complaint (Document 1-3) asserted a negligence claim against Defendant BioTE Medical LLC, a Texas company, as well as a claim for loss of consortium. The factual allegations describe hormone treatment administered by William Jarod Chapman, D.O., first at Living Well Medical Center, PLLC (LWMC) and later at The Facial Center (TFC), in accordance with training and protocols provided by BioTE. The Plaintiffs alleges that the hormone replacement therapy led Ms. Jeffries to develop elevated hormone levels 1 and cancer. They began complying with the pre-suit requirements of the West Virginia Medical Professional Liability Act (MPLA) as to Dr. Chapman, TFC, and LWMC around the same time they filed suit against BioTE. BioTE removed the matter to federal court on December 6, 2021. The Plaintiffs had not

yet served BioTE. BioTE filed a motion to dismiss on December 27, 2021. On January 10, 2022, having fulfilled the MPLA requirements, the Plaintiffs filed an Amended Complaint (Document 7), which added Dr. Chapman, LWMC, and Drs. Krajekian, Brock, Henderson, Di Prisco, and Revelo, Inc., d/b/a The Facial Center (TFC), as Defendants. The amended complaint includes more detailed factual allegations and alleges the following causes of action: Negligence, as to BioTE; Failure to Warn, as to BioTE; Strict Products Liability, as to BioTE; Medical Negligence, as to Dr. Chapman, LWMC, and TFC; and Loss of Consortium, as to all Defendants. Dr. Chapman, LWMC, and TFC are West Virginia residents, as are the Plaintiffs.

STANDARD OF REVIEW An action may be removed from state court to federal court if it is one over which the district court would have had original jurisdiction. 28 U.S.C. § 1441(a).1 This Court has original jurisdiction of all civil actions between citizens of different states or between citizens of a state and citizens or subjects of a foreign state where the amount in controversy exceeds the sum or

1 Section 1441 states in pertinent part:

Except as otherwise expressly provided by Act of Congress, any civil action brought in a State court of which the district courts of the United States have original jurisdiction, may be removed by the defendant or the defendants, to the district court of the United States for the district and division embracing the place where such action is pending.

28 U.S.C. § 1441(a). 2 value of $75,000, exclusive of interests and costs. 28 U.S.C. § 1332(a)(1)-(2). Generally, every defendant must be a citizen of a state different from every plaintiff for complete diversity to exist. Diversity of citizenship must be established at the time of removal. Higgins v. E.I. Dupont de Nemours & Co., 863 F.2d 1162, 1166 (4th Cir.1998).

Section 1446 provides the procedure by which a defendant may remove a case to a district court under Section 1441. Section 1446 requires that “[a] defendant or defendants desiring to remove any civil action from a State court shall file . . . a notice of removal signed pursuant to Rule 11 of the Federal Rules of Civil Procedure and containing a short and plain statement of the grounds for removal.” 28 U.S.C. § 1446(a). Additionally, Section 1446 requires a defendant to file a notice of removal within thirty days after receipt of the initial pleading. It is a long-settled principle that the party seeking to adjudicate a matter in federal court, through removal, carries the burden of alleging in its notice of removal and, if challenged, demonstrating the court’s jurisdiction over the matter. Strawn et al. v. AT &T Mobility, LLC et al., 530 F.3d 293, 296 (4th Cir. 2008); Mulcahey v. Columbia Organic Chems. Co., 29 F.3d 148, 151 (4th Cir. 1994) (“The burden of

establishing federal jurisdiction is placed upon the party seeking removal.”) (citation omitted). “If after removal the plaintiff seeks to join additional defendants whose joinder would destroy subject matter jurisdiction, the court may deny joinder, or permit joinder and remand the action to the State court.” 28 U.S.C. § 1447(e). “These are the only two options for a district court faced with a post-removal attempt to join a nondiverse defendant; the statute does not allow a district court to retain jurisdiction once it permits a nondiverse defendant to be joined in the case.” Mayes v. Rapoport, 198 F.3d 457, 462 (4th Cir. 1999) (noting that even where the rules would otherwise allow a plaintiff to amend without court approval, courts may reject the

3 amendment and joinder under §1447(e)). “Under Section 1447(e), the actual decision on whether or not to permit joinder of a defendant under these circumstances is committed to the sound discretion of the district court.” Id. Factors to consider in determining whether joinder of non- diverse parties should be permitted include: “the extent to which the purpose of the amendment is

to defeat federal jurisdiction, whether the plaintiff has been dilatory in asking for amendment, whether the plaintiff will be significantly injured if amendment is not allowed, and any other factors bearing on the equities.” Id. (quoting Gum v. Gen. Elec. Co., 5 F. Supp. 2d 412, 414 (S.D.W. Va. 1998) (Haden, C.J.)). If a defendant can prove that the non-diverse defendants were fraudulently joined, “that fact should be a factor—and perhaps the dispositive factor—that the court considers in deciding whether a plaintiff may join a nondiverse defendant.” Id. at 463. “The district court, with input from the parties, should balance the equities in deciding whether the plaintiff should be permitted to join a nondiverse defendant.” Id.

DISCUSSION The Plaintiffs explain that the original complaint named only BioTE as a defendant because suit had to be filed before expiration of the statute of limitations, while the anticipated claims against the in-state medical providers were tolled during the MPLA process.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Strawn v. AT & T MOBILITY LLC
530 F.3d 293 (Fourth Circuit, 2008)
Gum v. General Electric Co.
5 F. Supp. 2d 412 (S.D. West Virginia, 1998)
Higgins v. E.I. DuPont de Nemours & Co.
863 F.2d 1162 (Fourth Circuit, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
Jeffries v. BioTE Medical, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jeffries-v-biote-medical-llc-wvsd-2022.